We are developing a low toxicity form of rapamycin, an mTOR inhibitor; mTOR activity is increased in cancer. To get eRapa approved efficiently, we have chosen the rare disease, Familial Adenomatous Polyposis (FAP) where 100's to 1000's of polyps form in the colon and rectum as early as the teen years. 100% of these patients will develop colorectal cancer. After approval, we will expand to all high risk colorectal patients, then to other cancers.